This company is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Aerie Pharmaceuticals Toekomstige groei
Future criteriumcontroles 4/6
Belangrijke informatie
67.5%
Groei van de winst
78.4%
Groei van de winst per aandeel
| Pharmaceuticals winstgroei | 19.4% |
| Inkomstengroei | 19.3% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Good |
| Laatst bijgewerkt | n/a |
Recente toekomstige groei-updates
Recent updates
Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2024 | 226 | -26 | -2 | 41 | 8 |
| 12/31/2023 | 180 | -64 | -56 | 6 | 10 |
| 12/31/2022 | 138 | -123 | -89 | -1 | 5 |
| 9/30/2022 | 214 | -37 | 3 | 7 | N/A |
| 6/30/2022 | 207 | -49 | -5 | 0 | N/A |
| 3/31/2022 | 201 | -69 | -11 | -7 | N/A |
| 12/31/2021 | 194 | -75 | -102 | -99 | N/A |
| 9/30/2021 | 104 | -166 | -50 | -47 | N/A |
| 6/30/2021 | 95 | -166 | -53 | -50 | N/A |
| 3/31/2021 | 86 | -176 | -56 | -53 | N/A |
| 12/31/2020 | 83 | -183 | -68 | -65 | N/A |
| 9/30/2020 | 83 | -192 | -127 | -114 | N/A |
| 6/30/2020 | 82 | -202 | -142 | -130 | N/A |
| 3/31/2020 | 79 | -201 | -158 | -144 | N/A |
| 12/31/2019 | 70 | -200 | -168 | -150 | N/A |
| 9/30/2019 | 60 | -196 | -165 | -155 | N/A |
| 6/30/2019 | 48 | -232 | -175 | -160 | N/A |
| 3/31/2019 | 35 | -240 | -188 | -160 | N/A |
| 12/31/2018 | 24 | -233 | -184 | -153 | N/A |
| 9/30/2018 | 10 | -240 | -196 | -147 | N/A |
| 6/30/2018 | 2 | -187 | -172 | -125 | N/A |
| 3/31/2018 | N/A | -160 | -144 | -109 | N/A |
| 12/31/2017 | N/A | -145 | -120 | -93 | N/A |
| 9/30/2017 | N/A | -116 | -97 | -86 | N/A |
| 6/30/2017 | N/A | -107 | -93 | -86 | N/A |
| 3/31/2017 | N/A | -102 | -91 | -85 | N/A |
| 12/31/2016 | N/A | -99 | -85 | -80 | N/A |
| 9/30/2016 | N/A | -90 | -78 | -75 | N/A |
| 6/30/2016 | N/A | -84 | N/A | -66 | N/A |
| 3/31/2016 | N/A | -80 | N/A | -62 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: 0P0 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.03%).
Winst versus markt: 0P0 is forecast to become profitable over the next 3 years, which is considered above average market growth.
Hoge groeiwinsten: 0P0 is expected to become profitable in the next 3 years.
Omzet versus markt: 0P0's revenue (19.3% per year) is forecast to grow faster than the German market (3.6% per year).
Hoge groei-inkomsten: 0P0's revenue (19.3% per year) is forecast to grow slower than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if 0P0's Return on Equity is forecast to be high in 3 years time